Additionally, a randomized phase III trial assessing the superiority of osimertinib to first-generation EGFR-TKIs (gefitinib or erlotinib) was conducted in treatment-naïve patients with EGFR-mutated NSCLC [2]. Here, EGFR is linked to non-small cell lung carcinoma.